The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial

Background p38 mitogen-activated protein kinase (MAPK) plays a central role in the regulation and activation of pro-inflammatory mediators. COPD patients have increased levels of activated p38 MAPK, which correlate with increased lung function impairment, alveolar wall inflammation, and COPD exacerbations. Objectives These studies aimed to assess the effect of p38 inhibition with AZD7624 in healthy volunteers and patients with COPD. The principal hypothesis was that decreasing lung inflammation via inhibition of p38α would reduce exacerbations and improve quality of life for COPD patients at high risk for acute exacerbations. Methods The p38 isoform most relevant to lung inflammation was assessed using an in situ proximity ligation assay in severe COPD patients and donor controls. Volunteers aged 18–55 years were randomized into the lipopolysaccharide (LPS) challenge study, which investigated the effect of a single dose of AZD7624 vs placebo on inflammatory biomarkers. The Proof of Principle study randomized patients aged 40–85 years with a diagnosis of COPD for >1 year to AZD7624 or placebo to assess the effect of p38 inhibition in decreasing the rate of exacerbations. Results The p38 isoform most relevant to lung inflammation was p38α, and AZD7624 specifically inhibited p38α and p38β isoforms in human alveolar macrophages. Thirty volunteers were randomized in the LPS challenge study. AZD7624 reduced the increase from baseline in sputum neutrophils and TNF-α by 56.6% and 85.4%, respectively (p<0.001). In the 213 patients randomized into the Proof of Principle study, there was no statistically significant difference between AZD7624 and placebo when comparing the number of days to the first moderate or severe exacerbation or early dropout. Conclusion Although p38α is upregulated in the lungs of COPD patients, AZD7624, an isoform-specific inhaled p38 MAPK inhibitor, failed to show any benefit in patients with COPD.

[1]  D. Postma,et al.  The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials , 2017, International journal of chronic obstructive pulmonary disease.

[2]  M. R. Siddiqui,et al.  Global Initiative for Chronic Obstructive Lung Disease (GOLD) , 2017 .

[3]  I. Pavord,et al.  Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD , 2015, Thorax.

[4]  Shuying Yang,et al.  A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with ≤2% and >2% blood eosinophils. , 2015, Respiratory medicine.

[5]  E. R. Sutherland,et al.  CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.

[6]  F. Martinez,et al.  Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial , 2015, The Lancet.

[7]  S. Suissa,et al.  Inhaled corticosteroids in COPD: the clinical evidence , 2014, European Respiratory Journal.

[8]  I. Wilkinson,et al.  Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease , 2014, American Journal of Cardiovascular Drugs.

[9]  B. Nordestgaard,et al.  Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. , 2013, JAMA.

[10]  F. Martinez,et al.  Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. , 2013, The Lancet. Respiratory medicine.

[11]  W. MacNee,et al.  Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial , 2013, Thorax.

[12]  Dave Singh,et al.  Inhaled LPS challenges in smokers: a study of pulmonary and systemic effects. , 2012, British journal of clinical pharmacology.

[13]  S. Stanojevic,et al.  Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations , 2012, European Respiratory Journal.

[14]  P. Wollmer,et al.  Inhalation of LPS induces inflammatory airway responses mimicking characteristics of chronic obstructive pulmonary disease , 2012, Clinical physiology and functional imaging.

[15]  P. Calverley,et al.  Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study , 2011, European Respiratory Journal.

[16]  E. Regan,et al.  Genetic Epidemiology of COPD (COPDGene) Study Design , 2011, COPD.

[17]  F. Martinez,et al.  Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD , 2011, Respiratory research.

[18]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[19]  Dean M. Messing,et al.  Anti-Inflammatory Properties of a Novel N-Phenyl Pyridinone Inhibitor of p38 Mitogen-Activated Protein Kinase: Preclinical-to-Clinical Translation , 2009, Journal of Pharmacology and Experimental Therapeutics.

[20]  J. B. Buckton,et al.  p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression. , 2009, Journal of medicinal chemistry.

[21]  T. Murphy,et al.  Infection in the pathogenesis and course of chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[22]  D. Postma,et al.  Increased systemic inflammation is a risk factor for COPD exacerbations. , 2008, Chest.

[23]  L. Fabbri,et al.  Increased activation of p38 MAPK in COPD , 2008, European Respiratory Journal.

[24]  S. Hurd,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[25]  B. Celli,et al.  Exacerbations of chronic obstructive pulmonary disease , 2007, European Respiratory Journal.

[26]  G. Donaldson,et al.  Inflammatory changes, recovery and recurrence at COPD exacerbation , 2007, European Respiratory Journal.

[27]  D. Niewoehner.  The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. , 2006, The American journal of medicine.

[28]  S. Johnston,et al.  Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. , 2006, American journal of respiratory and critical care medicine.

[29]  J. Saklatvala.  The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. , 2004, Current opinion in pharmacology.

[30]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[31]  R. Ahrens,et al.  Asthma stability after oral prednisone: a clinical model for comparing inhaled steroid potency. , 2001, American journal of respiratory and critical care medicine.

[32]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[33]  F. Hargreave,et al.  Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. , 1996, American journal of respiratory and critical care medicine.

[34]  H. Watz,et al.  Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. , 2014, The Lancet. Respiratory medicine.

[35]  M. Dentener,et al.  Evaluation of oral corticosteroids and phosphodiesterase-4 inhibitor on the acute inflammation induced by inhaled lipopolysaccharide in human. , 2007, Pulmonary pharmacology & therapeutics.